Novartis resumes production of radioligand therapy medicines

2022.06.30 11:06

FILE PHOTO: The company’s logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann/File Photo

ZURICH (Reuters) – Novartis said it resumed the production and delivery of radioligand therapy medicines after fixing the issues that had led to a temporary suspension of production last month.

“The company has remediated the issues that led to the temporary, voluntary suspension of production in May,” the Swiss drugmaker said in a statement, adding these issues did not affect patient safety.

Source